Menstrual Blood Stem Cells in Severe Covid-19

NCT05019287 ↗

Phase 1/2 Completed 29 enrolled Avicenna Research Institute Tehran University of Medical Sciences · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of menstrual blood stem cells. The improvement in the clinical, laboratory and radiological manifestations will be evaluated in treated patients compared with the control group.

Timeline

Start: 2021-04-17
Primary completion: 2021-05-21
Completion: 2021-06-09

Publications

Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F, Dehghan-Manshadi SA, Kazemnejad S. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Res Ther. 2022 Mar 7;13(1):96. doi: 10.1186/s13287-022-02771-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allogeneic human menstrual blood stem cells secretome	Other / unclassified	5 ml	Intravenous

Menstrual Blood Stem Cells in Severe Covid-19

Summary

Timeline

Publications

Drugs

Indications